Equities research analysts forecast that Allergan plc (NYSE:AGN) will report sales of $3.90 billion for the current fiscal quarter, Zacks Investment Research reports. Nineteen analysts have provided estimates for Allergan’s earnings, with estimates ranging from $3.85 billion to $3.99 billion. Allergan reported sales of $4.01 billion in the same quarter last year, which would suggest a negative year-over-year growth rate of 2.7%. The company is expected to issue its next quarterly earnings report on Thursday, August 2nd.
According to Zacks, analysts expect that Allergan will report full year sales of $15.29 billion for the current fiscal year, with estimates ranging from $15.00 billion to $15.64 billion. For the next fiscal year, analysts expect that the firm will post sales of $15.61 billion per share, with estimates ranging from $14.77 billion to $16.04 billion. Zacks’ sales averages are a mean average based on a survey of research analysts that follow Allergan.
Allergan (NYSE:AGN) last issued its quarterly earnings results on Monday, April 30th. The company reported $3.74 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.36 by $0.38. Allergan had a negative net margin of 11.94% and a positive return on equity of 8.53%. The business had revenue of $3.67 billion for the quarter, compared to analyst estimates of $3.59 billion. During the same period in the previous year, the business posted $3.35 earnings per share. The business’s revenue was up 2.8% compared to the same quarter last year.
A number of brokerages have recently issued reports on AGN. Cantor Fitzgerald set a $180.00 price target on shares of Allergan and gave the stock a “hold” rating in a research note on Monday, June 11th. Wells Fargo & Co restated a “buy” rating on shares of Allergan in a research report on Monday, June 11th. Bank of America upped their target price on shares of Allergan from $209.00 to $213.00 and gave the stock a “buy” rating in a research report on Tuesday, June 12th. Credit Suisse Group set a $213.00 target price on shares of Allergan and gave the stock a “buy” rating in a research report on Tuesday, June 12th. Finally, Mizuho upped their target price on shares of Allergan from $150.00 to $176.00 and gave the stock a “neutral” rating in a research report on Monday, June 11th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and fifteen have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $212.15.
Shares of Allergan stock traded up $0.93 on Monday, reaching $173.42. 1,997,015 shares of the stock were exchanged, compared to its average volume of 2,760,536. Allergan has a 1-year low of $142.81 and a 1-year high of $256.80. The company has a quick ratio of 0.94, a current ratio of 1.10 and a debt-to-equity ratio of 0.36. The firm has a market cap of $58.49 billion, a price-to-earnings ratio of 10.61, a price-to-earnings-growth ratio of 1.23 and a beta of 1.12.
The firm also recently declared a quarterly dividend, which was paid on Friday, June 15th. Shareholders of record on Friday, May 18th were issued a $0.72 dividend. This represents a $2.88 annualized dividend and a dividend yield of 1.66%. The ex-dividend date was Thursday, May 17th. Allergan’s dividend payout ratio (DPR) is presently 17.61%.
In other Allergan news, EVP William Meury sold 24,425 shares of the company’s stock in a transaction dated Thursday, May 17th. The shares were sold at an average price of $154.59, for a total value of $3,775,860.75. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.36% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Avestar Capital LLC purchased a new position in shares of Allergan during the fourth quarter valued at approximately $113,000. Focused Wealth Management Inc lifted its stake in shares of Allergan by 4,444.4% during the fourth quarter. Focused Wealth Management Inc now owns 818 shares of the company’s stock valued at $134,000 after buying an additional 800 shares during the period. Captrust Financial Advisors purchased a new position in shares of Allergan during the fourth quarter valued at approximately $175,000. Bfsg LLC purchased a new position in shares of Allergan during the first quarter valued at approximately $206,000. Finally, Wayne Hummer Investments L.L.C. purchased a new position in shares of Allergan during the first quarter valued at approximately $211,000. 79.16% of the stock is currently owned by institutional investors.
Allergan Company Profile
Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer's disease.
Get a free copy of the Zacks research report on Allergan (AGN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.